Early trial tests new shot to help immune system fight breast cancer
NCT ID NCT02950259
Summary
This small, early-stage study tested the safety of an experimental immune-boosting treatment called IRX-2. It was given as an injection near the breast tumor before patients with early-stage breast cancer had their standard surgery or chemotherapy. The main goal was to see if the treatment was safe and to check for early signs that it might help the body's immune cells attack the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Providence Portland Medical Center
Portland, Oregon, 97213, United States
Conditions
Explore the condition pages connected to this study.